These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 28798070)
1. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070 [No Abstract] [Full Text] [Related]
2. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome. Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870 [No Abstract] [Full Text] [Related]
11. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report. Hartsell L; Janes A; Larck C; Park S; Arnall JR J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164 [TBL] [Abstract][Full Text] [Related]